Labcorp Holdings Inc. Stock

Equities

LH

US5049221055

Healthcare Facilities & Services

Market Closed - Nyse 16:00:02 2024-05-28 EDT 5-day change 1st Jan Change
196.2 USD -1.73% Intraday chart for Labcorp Holdings Inc. -4.46% -13.68%
Sales 2024 * 12.8B 17.5B Sales 2025 * 13.4B 18.32B Capitalization 16.54B 22.61B
Net income 2024 * 940M 1.28B Net income 2025 * 1.08B 1.47B EV / Sales 2024 * 1.66 x
Net Debt 2024 * 4.71B 6.43B Net Debt 2025 * 3.97B 5.42B EV / Sales 2025 * 1.53 x
P/E ratio 2024 *
17.2 x
P/E ratio 2025 *
15 x
Employees 61,975
Yield 2024 *
1.5%
Yield 2025 *
1.54%
Free-Float 99.65%
More Fundamentals * Assessed data
Dynamic Chart
Some of the biggest splits in Corporate America RE
Declaration of Voting Results by Laboratory Corporation of America Holdings CI
Declaration of Voting Results by Laboratory Corporation of America Holdings CI
Declaration of Voting Results by Laboratory Corporation of America Holding CI
Laboratory Corp Of America Holdings Insider Sold Shares Worth $421,655, According to a Recent SEC Filing MT
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $256 From $255, Keeps Outperform Rating MT
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy CI
Tara Health Files an Exempt Solicitation Statement and Recommend Vote for its Proposal CI
Tranche Update on Laboratory Corporation of America Holdings (NYSE:LH)'s Equity Buyback Plan announced on December 9, 2021. CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $255 From $244 MT
Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy MT
US FDA publishes final rule for laboratory developed tests RE
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $244 From $255 MT
Barclays Adjusts Price Target on Laboratory Corp of America Holdings to $213 From $234 MT
More news
1 day-1.73%
1 week-4.46%
Current month-2.57%
1 month-1.11%
3 months-8.66%
6 months-7.60%
Current year-13.68%
More quotes
1 week
196.14
Extreme 196.14
201.16
1 month
196.14
Extreme 196.14
215.07
Current year
196.11
Extreme 196.11
234.09
1 year
195.01
Extreme 195.01
243.30
3 years
195.01
Extreme 195.01
317.17
5 years
98.02
Extreme 98.02
317.17
10 years
95.61
Extreme 95.61
317.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 13-03-31
Director of Finance/CFO 62 14-06-15
Compliance Officer 65 19-01-31
Members of the board TitleAgeSince
Chief Executive Officer 58 13-03-31
Director/Board Member 68 12-12-31
Director/Board Member 66 06-05-16
More insiders
Date Price Change Volume
24-05-28 196.2 -1.73% 743,619
24-05-24 199.6 +1.30% 724,589
24-05-23 197.1 -2.04% 677,754
24-05-22 201.2 -2.02% 780,917
24-05-21 205.3 -0.72% 594,249

Delayed Quote Nyse, May 28, 2024 at 04:00 pm

More quotes
Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
196.2 USD
Average target price
239.7 USD
Spread / Average Target
+22.16%
Consensus